Merck's M&A Focus Is On Early-Stage Deals: Licensing Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
During a panel at the BIO CEO & Investor conference, Merck's chief licensing officer talks about early-stage opportunities and admits big pharma is becoming more "outwardly facing" when it comes to innovation.